SINGH SHAWN (CHIEF EXECUTIVE OFFICER) received a stock award from VISTAGEN THERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 7/5/2023ACC: 0001415889-23-010721
DirectorOfficer· CHIEF EXECUTIVE OFFICER
Since Aug 2018
+167.00
Net shares
Net buyer
$265.45
Total acquired
0
Open market trades
0B · 0S
1
Total transactions
167.00 acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+167.00
Price / share
$1.59
Trade value
$265.45
% of position
3.2%
6/30/2023
5.30K→5.47K
Total
Net shares
+167.00
Net value
$265.45
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/30/2023 | A · Award | +167.00 | $1.59 | $265.45 | 3.2% | 5.30K | 5.47K |
| Total | +167.00 | $265.45 | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned20.88K
Total
20.88K indirect20.88K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 20.88K | Indirect |
| Total | 20.88K | 20.88K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported